Vir Biotechnology Insider Sold Days Before 44% HDV Readout
Vir Biotechnology reported 44% Phase 3 response rates in hepatitis delta, with ten patients achieving sustained viral response after 96 weeks off treatment. The company's general counsel sold shares o
Vir Biotechnology HDV Drug Hits 44% Phase 3 Response
NEW YORK, November 9 —
When Vir Biotechnology, Inc. (VIR) reported positive Phase 3 results in hepatitis delta on November 9, sending shares reportedly up more than 10% overnight, the company's EVP and General Counsel had already sold six days earlier at $11.10 to $11.33 per share. The person whose job includes overseeing insider trading compliance had reduced her stake.
- 44% Phase 3 response rate; 10 patients discontinued after 96+ weeks all achieved SVR12, suggesting functional cure potential in a subset.
- Vanina De Verneuil sold 3,750 shares November 2-3 for ~$41,939, six days before the Phase 3 readout.
- At $12.21 pre-surge, Vir's clinical enterprise value implied ~$1.7 billion; analyst consensus target was $21.50, a 76% gap predating today.
The HDV Win That Resets the Benchmark
Vir Biotechnology is a San Francisco clinical-stage company founded in 2016 with 367 employees that has never commercialized a product, focused on infectious disease and oncology. Its HDV program now has Phase 3 proof: a 44% response rate in an indication with few approved therapies, plus 10 patients who stopped dosing after 96 weeks and all achieved sustained viral response, the virology term for a functional cure in that subset. Approximately 26 days before this readout, Gilead Sciences agreed to pay up to $1.87 billion for three of Vir's PRO-XTEN T cell engager programs targeting solid tumors, giving the platform a partnership-validated external price.
The Timing the Filings Cannot Explain
Vanina De Verneuil is Vir's EVP, General Counsel, and Corporate Secretary, the executive whose job includes overseeing insider trading compliance. On November 2 and 3, she sold a combined 3,750 shares at $11.10 to $11.33, collecting approximately $41,939. The sales came one to two days before the November 4 Q3 earnings 8-K and six days before the Phase 3 results. Whether these were executed under a pre-planned Rule 10b5-1 schedule or were discretionary trades, the Form 4 filings do not say; without that disclosure, the timing sits unresolved against two back-to-back catalysts the stock had not yet priced in.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| VIR | $2.1B | n/a | +127.4% |
| CODX | $2M | n/a | -97.8% |
| VXRT | $90M | n/a | -7.5% |
| INO | $134M | n/a | -43.3% |
| BNTX | $21.7B | n/a | -16.7% |
| ARCT | $298M | n/a | +17.9% |
What the Next Catalyst Must Confirm
At the pre-surge price of $12.21, Vir's market cap was approximately $2.09 billion against $0.46 billion in cash, implying a clinical enterprise value of roughly $1.7 billion, almost exactly what Gilead is paying for three TCE programs alone. The 9.7% short interest amplifies any re-rating, and analyst consensus already stood at $21.50 before the readout. The full Phase 3 regulatory path and any acquisition discussions will be the next tests; at approximately $141 million in annual operating cash burn, net cash of $370 million funds roughly 2.5 years of runway. Run the free Vir Biotechnology, Inc. deep-dive → and use the DCF calculator to stress-test the valuation.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What were Vir Biotechnology's Phase 3 HDV results?
Vir Biotechnology reported a 44% Phase 3 response rate in hepatitis delta on November 9. Additionally, ten patients who discontinued dosing after 96 weeks all achieved SVR12, suggesting functional cure potential in that subset.
When did Vir's general counsel sell shares?
Vir's EVP and General Counsel Vanina De Verneuil sold 3,750 shares on November 2-3 for approximately $41,939, six days before the Phase 3 results. The Form 4 filings do not disclose whether these were pre-planned Rule 10b5-1 trades or discretionary trades, leaving the timing unresolved.
How much did Vir Biotechnology stock jump on the news?
Vir's shares reportedly rose more than 10% overnight following the November 9 Phase 3 announcement. At the pre-surge price of $12.21, the company's clinical enterprise value was roughly $1.7 billion, while analyst consensus target stood at $21.50.
What is Vir Biotechnology's business?
Vir Biotechnology is a San Francisco clinical-stage company founded in 2016 with 367 employees that has never commercialized a product. The company focuses on infectious disease and oncology, and recently received a $1.87 billion acquisition offer from Gilead for three of its T cell engager programs.
How long can Vir Biotechnology fund operations?
At approximately $141 million in annual operating cash burn, Vir's net cash of $370 million funds roughly 2.5 years of runway.
Vir Biotechnology's experimental hepatitis delta drug met its Phase 3 primary endpoint with a 44% response rate today, reportedly lifting shares more than 10%, just weeks after Gilead Sciences agreed to pay up to $1.87 billion for three of Vir's T cell engager programs. What the headline does not explain is why the company's own chief legal officer sold shares two days before the Q3 earnings release and six days before this clinical readout.